Mega Genomics

Mega Genomics ROE

The Return on Equity (ROE) of Mega Genomics (6667.HK) as of Oct 16, 2026 is 4.31 %. In the previous year, Return on Equity (ROE) was 7.33 % — a change of -41.21% (lower).

ROE

4.31 %

YoY

-41.21%

Last updated:

In 2025, Mega Genomics's return on equity (ROE) was 4.31 %, a -41.21% increase from the 7.33 % ROE in the previous year.

The Mega Genomics ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
-1,098.85 CNY
Jan 1, 2020
44.84 CNY
Jan 1, 2021
9.75 CNY
Jan 1, 2022
-2.44 CNY
Jan 1, 2023
4.66 CNY
Jan 1, 2024
7.33 CNY
Jan 1, 2025
4.31 CNY
The Mega Genomics ROE history
YEARROEYoY
4.31 %-41.21%
7.33 %+57.31%
4.66 %-290.61%
-2.44 %-125.06%
9.75 %-78.25%
44.84 %-104.08%
-1,098.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Mega Genomics Stock analysis

What does Mega Genomics do? Mega Genomics Ltd, listed on the Hong Kong Stock Exchange under ticker 6667.HK with ISIN KYG5960G1047, is a health care company headquartered in Beijing, China. The company, which went public on June 22, 2022, employs 267 full-time staff. Mega Genomics operates as a genetic testing platform, offering consumer genetic testing and cancer screening services. Its business is structured into three segments. The Consumer Genetic Testing Services segment provides tests related to nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, pharmacogenetic testing, and infectious disease testing. The Cancer Screening Services segment offers specific tests including the Septin9 colorectal cancer screening test, Syndecan-2 (SDC2) colorectal cancer screening test, and the ring finger protein 180 (RNF180)/Septin9 gastric cancer screening test. The Other Services segment delivers genetic research and analysis services to third-party research institutions. The company's website is https://www.megagenomics.cn/. Mega Genomics focuses on providing genetic testing solutions for both consumer and clinical applications, with an emphasis on cancer-related screening and personalized health assessments. The company's operations are based in Beijing, reflecting its position within China's growing health care sector. As a publicly traded entity, Mega Genomics is subject to the regulatory requirements of the Hong Kong Stock Exchange. Mega Genomics is one of the most popular companies on Eulerpool.

ROE Details

Decoding Mega Genomics's Return on Equity (ROE)

Mega Genomics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Mega Genomics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Mega Genomics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Mega Genomics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Mega Genomics stock

Return on Equity (ROE) of Mega Genomics is 4.31 % in 2025.

Return on Equity (ROE) of Mega Genomics changed from 7.33 % to 4.31 %, representing a -41.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Mega Genomics since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Mega Genomics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Mega Genomics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Mega Genomics